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EŽƚWĂƌƚŝĐƵůĂƌůǇ^ƉĞĐŝĂů PĐƌŝƚŝƋƵŝŶŐ ?EW^ ?ĂƐ
ĂĐĂƚĞŐŽƌǇŽĨĚƌƵŐƐ 
Abstract 
Novel Psychoactive Substances (NPS) have been a dominant feature of drug discourse for many years 
now and, in academic, policy and public discourse, have become established as a new  ? and by 
implication, distinct  ? category of drugs. We argue that this understanding of NPS is fundamentally 
problematic. Differences within the category are obscured, as are similarities between NPS and more 
established categories of drugs. Focusing on NPS as something new, different or particularly special is 
misleading and counterproductive and can have serious consequences in terms of understanding the 
bigger picture in relation to illegal drugs more generally. This has led to overestimations of the size of 
the NPS problem, obfuscation of the common underlying causes of dependent drug use, and the 
implementation of significant and problematic policy changes. Further, a failure to see the rise in NPS 
as just one of a number of emerging trends in contemporary drug scenes, alongside the development 
of online markets or the rise in domestic drug production operations, for example, impairs our ability 
to understand the wider societal, cultural and theoretical underpinnings of drug use. NPS are not 
particularly special: treating them as such can have dangerous and far-reaching consequences.  
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NPS, as a category of drugs, is a relatively recent construct, but has become firmly established in the 
lexicon of drug research and policy. NPS stands for Novel (or New) Psychoactive Substances  W 
something of a catch-all term for drugs not otherwise known, or at least not well-recognised, either 
in established drug culture or in existing legal or academic categories. It is an inherently vague 
category, but has proven popular, at least on a rhetorical level: media, researchers and policy 
makers uncritically use the term despite, or because of, the fact that it incorporates a diverse range 
of substances with a diverse range of issues associated with them.  NPS have thus become a 
dominant and distinct theme in the worlds of drug policy, research and discourse. This has had far-
reaching and significant consequences  W for example, in terms of policy formulation and impact on 
the experience of users. It is therefore worthy of critical exploration, as we illustrate here taking the 
UK as an example.   
 
In 2010, in response to widespread concerns about the use of new substances such as mephedrone 
and synthetic cannabinoids, ƚŚĞh<ŝŶƚƌŽĚƵĐĞĚ ‘ĞŵĞƌŐĞŶĐǇ ?ůĞŐŝƐůĂƚŝŽŶĂůůŽǁŝŶŐŶĞǁƐƵďƐƚĂŶĐĞƐƚŽ
be temporarily banned on the presumption of harm to prevent widespread use occurring before 
control measures could be implemented.  In 2016, the UK government took a further substantial 
step via the introduction of the Psychoactive Substances Act (PSA), which bans the supply of all 
substances that have a potential psychoactive effect when consumed.  It is notable that substances 
as common (and in some cases necessary) as food, caffeine, nicotine and alcohol have had to be 
specifically listed as exemptions under the act.  These two steps represent not just a significant and 
enduring change in UK drug control, but in terms of legislative power in general.  Previously, new 
substances would be subjected to scientific analysis and risk assessment before justifying and 
enacting legal controls. Now the proof of harm is no longer required and substances are, de facto, 
controlled on the blanket presumption of harm (Stevens et al, 2015). 
 
Policy changes such as those witnessed in the UK, based on the presumption that NPS need to be 
treated differently from other existing substances, can also have wide reaching consequences for 
particular groups of people.  Remaining with the UK as an example, an argument erupted in March 
2016 about the inclusion of amyl nitrates (poppers) within the PSA. Crispin Blunt, a British MP, 
supported by the wider LGBT community, successfully argued that its harms were negligible and that 
a whole population of gay men (who often use the substance because of its muscle relaxing 
properties) would be criminalised if it was included in the act, and managed to secure a last minute 
exemption ďĂƐĞĚŽŶƚŚĞŝƌ “ĐŽŵƉůĞƚĞůǇŚĂƌŵůĞƐƐ ?ŶĂƚƵƌĞ ?ŝŵŽůĚĞŶďĞƌŐ ? ? ? ? ?:1).  Contrastingly, 
users of nitrous oxide, another substance widely believed to be of negligible harm (Winstock, cited in 
Ruz, 2015), were not able to secure exemption from the act and recent evidence shows that 71% of 
arrests made under the act have in fact been for nitrous oxide (Harry, 2017) which is notoriously 
bulky to carry around and therefore easy to detect (it is usually obtained in heavy aluminium 
canisters). (Incidentally, recent court cases brought in the UK under the PSA in relation to nitrous 
oxide have been abandoned due to debate over nitrous oxide ?s legitimate medical uses with a 
lawyer successfully arguing that they are therefore not covered by the PSA (Farand, 2017).) 
 
As the examples above demonstrate, the changes imposed by the presumption that NPS constitute a 
distinct category of substances that present a significant problem to societies and existing systems of 
drug control, can have serious consequences, particularly for certain groups of people. Yet, we 
suggest, it is not just policymakers and the media that have bought into this need for emphasis and 
distinction of these substances, but also academics. For example, NPS themed panels are regular 
constituents of the annual conference of the International Society for the Study of Drug Policy; seven 
out of 26 papers on the programme for the European Society for Social Drug research (ESSD) 2017 
conference ŚĂĚ ‘NPS ? in their titles; and leading drug journals have dedicated NPS-themed special 
issues. Of course, academics should respond to the issues of the day  W particularly those working in 
the field of policy, or those seeking to understand contemporary social issues. But the papers that 
discuss NPS, and which are lumped together in special issues or on conference panels, tend to focus 
on a wide and differing range of actual substances. Critiques in this area exist, but mainly address 
the flawed and unworkable policy making process in this area (Stevens et al, 2015; Reuter & Pardo, 
2017) or the failure to consider the need for harm reduction as part of the NPS policy response (van 
ŵƐƚĞƌĚĂŵĞƚĂů ? ? ? ? ? ?DĞĂƐŚĂŵ ? ? ? ? ? ?K ?ƌŝĞŶĞƚĂů ? ? ? ? ?).  
 
While we regard these critiques as important, we suggest that they obscure a bigger problem: NPS 
have become accepted as a distinct category of drugs, even, albeit inadvertently, by many of those 
writers critical of policy responses.  Here, we wish to build on the work of Barratt et al (2017) and 
Measham & Newcombe (2016).   Barratt et al (2017: 23), as part of a critical analysis of the term 
 ‘ƉƐǇĐŚŽĂĐƚŝǀĞ ?ŝŶƵƐƚƌĂůŝĂŶĚƌƵŐƉŽůŝĐǇ ?ĞŵƉŚĂƐŝƐĞƚŚĞůŝŬ ůǇƉƌŽďůĞŵƐƚŚĂƚǁŝůůďĞĐĂƵƐĞĚďǇ
treating NPS as a single category, and invite researcŚĞƌƐƚŽĐŽŶƐŝĚĞƌ P “What are the implications of 
this framing of NPS, and the possible conflation or non-differentiation of substances?  What does it 
ŵĞĂŶǁŚĞŶǁĞƐĞĞǀĂƌŝĂďŝůŝƚǇ ?ŵƵůƚŝƉůŝĐŝƚǇĂŶĚĚŝĨĨĞƌĞŶĐĞŽďƐĐƵƌĞĚŽƌĞƌĂƐĞĚŝŶƚŚŝƐǁĂǇ ? ?  
Furthermore, Measham & Newcombe (2016) suggest that one of the consequences of categorising 
EW^ĂƐĂ ‘ŶĞǁ ?ƉƌŽďůĞŵŝƐƚŽŽďƐĐƵƌĞĐŽŶŶĞĐƚŝŽŶƐĂŶĚĐŽŶƚŝŶƵŝƚŝĞƐǁŝƚŚƚŚĞǁŝĚĞƌĚƌƵŐƐĨŝĞůĚ ? 
 
Our article documents the construction of NPS as a distinct category, but argues that the creation of 
the category itself has resulted in significant consequences while having no meaningful coherence 
nor academic utility. To discuss it as if it does obscures both the differences between substances 
within the NPS category and the similarities between NPS and other illicit substances.  These 
obfuscations hold significant consequences in terms of the public discourses and policy responses 
that we create around NPS, and, perhaps most importantly, the development of theoretical 




Constructing the category NPS 
 
 ‘EĞǁ ?drugs, destined to become categorised as illegal, have consistently appeared on the scene 
throughout the history of global drug control: the primary function, for example, of the 1971 
Convention on Psychotropic Substances was to bring a substantial list of psychoactive substances 
not covered by the 1961 Single Convention on Drugs under the framework of international drug 
control.  What has changed, in recent years, is their  “range, potency, profile and availability ? 
(Winstock & Ramsey, 2010: 1685).  The rising role that the internet plays in drug markets (Barratt 
and Aldridge, 2016), and the increasing blurring of the boundaries between licit and illicit substances 
(prescription medicines, human enhancement drugs, lifestyle drugs) has allowed for easier 
marketing and distribution of substances which, in turn, has meant more people are willing to focus 
on the development of new drugs.  This has led to a fundamental change in the way that new drugs 
are conceptualised.  Rather than being treated on an individual basis (as was the case when MDMA 
ďĞĐĂŵĞƉŽƉƵůĂƌŝŶƚŚĞ ‘ƌĂǀĞ ?ƐĐĞŶĞin the 1980s, or when Ketamine use spread in the 1990s), or 
ŝŐŶŽƌĞĚĂƐďĞŝŶŐƚŽŽ ‘ƵŶĚĞƌƚŚĞƌĂĚĂƌ ?ƚŽďĞǁŽƌƚŚǇŽĨĂĐĂĚĞŵŝĐĂƚƚĞŶƚŝŽŶŽƌƉƵďůŝĐĐŽŶĐĞƌŶ ?as was 
the case with both MDMA and Ketamine when they first emerged), they have come to be treated as 
a category of drugs in their own right. This means that hundreds of substances, often with quite 
different effects  W and quite different associated problems  W are lumped together.  At first these 
ƐƵďƐƚĂŶĐĞƐǁĞƌĞŽĨƚĞŶƌĞĨĞƌƌĞĚƚŽĂƐ ‘ůĞŐĂůŚŝŐŚƐ ? ?ƐŝŐŶĂůůŝŶŐƚŚĂƚƚŚĞǇĨĞůůŽƵƚƐŝĚĞƚŚĞƚĞƌŵƐŽĨ
ĞǆŝƐƚŝŶŐŶĂƚŝŽŶĂůĂŶĚŝŶƚĞƌŶĂƚŝŽŶĂůĚƌƵŐĐŽŶƚƌŽůůĞŐŝƐůĂƚŝŽŶ ?Žƌ ‘ĚĞƐŝŐŶĞƌĚƌƵŐƐ ? or  ‘ƌĞƐĞĂƌĐŚ
ĐŚĞŵŝĐĂůƐ ?, reflecting their manufactured nature.  More recently, ƚŚĞǇŚĂǀĞďĞĞŶƚĞƌŵĞĚ ‘ŶĞǁ ?Žƌ
 ‘ŶŽǀĞů ?ƉƐǇĐŚŽĂĐƚŝǀĞƐƵďƐƚĂŶĐĞƐ ?EW^ ) ? 
 
Europe has played a pivotal role in the NPS category construction since a 1997 Joint Action 
(European Council, 1997) on the control of new synthetic drugs established a mechanism for 
information exchange, risk assessment and control.  This categorisation was later solidified in a 2005 
Framework Decision (Council of the European Union, 2005) in the same area, representing the 
highest level of European integrated drug control.  Taken collectively, these pieces of international 
drug legislation set the scene for treating NPS as a distinct category and necessitating the 
development of new legislation, over and above that which already existed, to control them. Since 
1997, many countries around the globe have ascribed to this general categorisation of NPS and have 
initiated policy responses directed specifically towards them.  The United Nations Office on Drugs 
and Crime (UNODC) has recently developed its own Early Warning Advisory to share information on 
NPS on a global scale.  The European Early Warning System identified 14 new substances in 2005, 
with numbers increasing exponentially since.  In 2015, 98 new substances were reported, with a 
further 66 in 2016, bringing the total number of new substances being monitored to 620 (EMCDDA, 
2017).  
 
There have been some attempts to break down the categorisation of NPS into different groupings.  
Newcombe (2015) describes different attempts at sub-categorising NPS as related to where they 
come from (source), how they are regulated (legal), how they affect the brain 
(psychopharmacological) and their chemical groupings (psycho-chemical).  Based on the latter two 
approaches, the UNODC (2013) have identified nine broad categories of NPS: synthetic cannabinoid 
receptor agonists (e.g. JWH-K ? ? ? ‘^ƉŝĐĞ ? ) ?ĂŵŝŶŽŝŶĚĂnes (e.g. MDAI); synthetic cathinones (e.g. 
mephedrone); tryptamines (e.g. 5-MEO-DPT); ketamine and phencyclidine type substances (e.g. 4-
MeO-PCP); piperazines (e.g. benzylpiperazine); phenethylamines (e.g. Bromo-DragonFLY); plant 
based substances (e.g. Khat) and other substances (e.g. DMAA).  Two of these categories remain 
ƉĂƌƚŝĐƵůĂƌůǇƉƌŽďůĞŵĂƚŝĐ ? ‘WůĂŶƚďĂƐĞĚƐƵďƐƚĂŶĐĞƐ ?ĂŶĚ ‘ŽƚŚĞƌƐƵďƐƚĂŶĐĞƐ ?ĐĂŶŝŶĐůƵĚĞdrugs with a 
wide range of chemical compositions  W and hence a wide range of psychoactive effects. And Khat, 
often used as the foremost example of plant based new substances, has been culturally normalised 
in East Africa for hundreds of years (Anderson et al., 2007).  Ultimately, however, this attempt at 
sub-categorising NPS begs the question why they are divided into their own sub-categories rather 
than being subsumed under more general attempts to categorise illicit substances.  For example, the 
vast majoƌŝƚǇŽĨEW^ĐŽƵůĚďĞŝŶĐŽƌƉŽƌĂƚĞĚŝŶƚŽĂŶĞǆŝƐƚŝŶŐƐǇƐƚĞŵƐƵĐŚĂƐĚůĞǇ ?Ɛ ? ? ? ? ? ) ?ǁŚŝĐŚ
employs the categories stimulants, empathogens, psychedelics, dissociatives, cannabinoids, 
depressives and opioids. 
 
 
Deconstructing the category NPS 
 
Separating NPS from other existing drugs is problematic in numerous ways.  Firstly, there are 
problems with the naming of the category, starting ǁŝƚŚƚŚĞƚĞƌŵ ‘ŶŽǀĞů ?Žƌ ‘ŶĞǁ ?: how long does 
something remain new for and when, if ever, do drugs stop being novel and become decategorised? 
It must be acknowledged that the specific substances which ĂƌĞŽƌĂƌĞŶŽƚŝŶĐůƵĚĞĚƵŶĚĞƌ ‘EW^ ?
varies wildly  W there are regional, jurisdictional and discipline-centred variations and a review of the 
various papers we cite in this article demonstrates the lack of consensus about which drugs should 
be included or what an exact definition of NPS might be. As such, NPS often includes drugs that have 
been with us for ages (e.g., Ketamine, 2CB, GHB, GBL), while usually excluding other notable 
synthetic chemicals such as MDMA, or the 230+ psychoactive compounds discovered and 
experimented with by Alexander and Anne Shulgin, documented in their books PiHKAL: A Chemical 
Love Story (1990) and TiHKAL: The Continuation (1997)1.  ŽĞƐ ‘ŶĞǁ ?ƌĞĨĞƌƚŽŶĞǁůǇĚŝƐĐŽǀĞƌĞĚ ?Žƌ
re-discovered), newly marketed, newly formulated, or newly used in more widespread (sub)cultural 
contexts (Newcombe, 2015)? This is more than a semantic criticism: ƚŚĞůĂďĞů ‘ŶĞǁ ?ŝŵƉůŝĞƐƚŚĂƚǁĞ
have limited knowledge of a substance (e.g., of patterns of use or associated harms) which may 
suggest a different policy  W or academic  W response compared to where we have an established 
evidential base to inform us. 
 
dŚĞƌĞĂƌĞĂůƐŽƉƌŽďůĞŵƐǁŝƚŚƚŚĞƚĞƌŵ ‘ƉƐǇĐŚŽĂĐƚŝǀĞ ?, usually defined as leading to (significant) 
changes to the state of the central nervous system and/or inducing dependence. This has come 
under scrutiny because of blanket ban legislation, which has been enforced against all psychoactive 
substances in a growing number of countries (Ireland, Poland, Romania, New Zealand, Australia and 
the UK to date; Barratt et al., 2017).   In a critique of UK legislation against psychoactive substances, 
Stevens et al. (2015) remind us that not all such substances are harmful (e.g. lavender oil, morning 
glory seeds), that many have legitimate uses (e.g. nitrous oxide), and that the psychoactive effects of 
substances about which very little is known can be hard to determine. Barratt et al. (2017), critiquing 
ƵƐƚƌĂůŝĂŶůĞŐŝƐůĂƚŝŽŶ ?ďƵŝůĚŽŶƚŚĞƐĞĂƌŐƵŵĞŶƚƐƚŽĚƌĂǁŽƵƚƚŚĞĚĂŶŐĞƌƐŽĨĞƋƵĂƚŝŶŐ ‘ƉƐǇĐŚŽĂĐƚŝǀĞ ?
                                                          
1 dŚĞƚŝƚůĞƐŽĨƚŚĞƐĞƚǁŽďŽŽŬƐĂƌĞĂĐƌŽŶǇŵƐĨŽƌ ‘Phenethylamines I Have Known And Loved ?ĂŶĚ ‘Tryptamines 
I Have Known And Loved ? ? 
ǁŝƚŚ ‘ŚĂƌŵĨƵůĂŶĚǁŽƌƚŚǇŽĨĐŽŶƚƌŽů ? PĚŽŝŶŐƐŽŵĂŬĞƐƚŚĞƉƐǇĐŚŽůŽŐŝĐĂůĞĨĨĞĐƚƐŽĨŝŶĚŝǀŝĚƵĂů
substances seem stable and unchanging, rather than subjective and varying. It also disassociates 
them from the cultural contexts in which they are taken and thus disregards well-established work 
on the importance of contexts of drug use (see e.g. ŝŶďĞƌŐ ?Ɛ ? ? ? ? ?) work on set and setting). 
 
&ŝŶĂůůǇ ?ƚŚĞƌĂŶŐĞŽĨ ‘ƐƵďƐƚĂŶĐĞƐ ?that have been included in the category (subject to the variations 
of use mentioned above) is highly problematic.  There are a huge number of these with a widely 
varying range of effects and chemical make-ups.  Further, the substances included within the 
umbrella term seem arbitrary.  Why, for example, are ketamine (first synthesised in 1962) and 
Nitrous Oxide (1772) sometimes referred to as NPS, while mephedrone (1929) is always included, 
but MDMA (1912) almost never is?  Even more striking, however, is the fact that over the same 
period as the emergence of NPS as a category, another huge grouping of new substances has also 
emerged: human enhancement drugs (HED).  These can be divided into six categories (Evans-Brown 
et al, 2012): muscle drugs (e.g. Anabolic-Androgenic Steroids); weight loss drugs (e.g. Xenical); image 
enhancing drugs (e.g. Melatonin); sexual enhancers (e.g. Viagra); cognitive enhancers (e.g. Ritalin); 
and mood and behaviour enhancers (e.g. Diazepam). Despite many of these categories containing 
the potential for psychoactive effect, and despite clear overlap in terms of their marketing and 
distribution, these substances receive a fraction of the attention to those ascribed the label NPS, and 
are rarely discussed in the same fora (Chatwin et al, 2017).  
 
Semantics aside, there are further problems in the creation of this new category.  Typologies and 
categories become useful when we have lots of variation in some broad class of things (e.g., drugs) 
and can group individual examples together because they share characteristics that are important 
for understanding the broader class and its component categories. Typologies reflect not just 
important similarities across those examples within the same type, but also important differences 
between categories. For NPS to be a useful category, scientifically, there should be recognised 
similarities across the substances within that category and important differences between those 
substances categorised as NPS and those that are not. It is not clear that anything objectively unites 
NPS in a way that also delineates them from pre-existing categories of illicit drugs, or from 
psychoactive substances as a whole.  Creating the category NPS therefore leads to two significant, 
overlapping problems: it obscures both the differences between substances within the category and 
the similarities between NPS and other illicit substances. The consequences of these obfuscations 
are explored next.  
 
Consequences of missing the bigger picture 
 
Public Discourse 
One of the important consequences of conflating the hundreds of NPS emerging onto the scene into 
one category is to inflate the apparent size of the problem.  The figures on numbers of new drugs 
discovered, for example by the EU or UNODC systems, suggest that this is a situation spiralling out of 
control.  International bodies charged with monitoring the drug problem have flagged the issue as 
the latest challenge facing national and international systems of drug control (European 
Commission, 2011; INCB, 2011).  A more in-depth perusal of the figures, however, suggests that, 
while the numbers of identified new substances is high and continues to increase, the problem may 
not be as large as often portrayed.  
 
While most regions in the world confirm the appearance of NPS within their internal drug markets 
(UNODC, 2013), the limited information that is available on prevalence rates suggests that they 
remain relatively low.  In the UK, for example, only 0.7% of the adult population reported having 
used any of the 560+ NPS in the last year (Gromyko, 2016).  This appears small when compared with 
the  ? ? ?A?ǁŚŽŚĂĚƚĂŬĞŶ ‘ĂŶǇĚƌƵŐ ? ?ĂĐĂƚĞŐŽƌǇƚŚĂƚĚŽĞƐŶ ?ƚŝŶĐůƵĚĞ EW^ and which actually now 
includes fewer drugs than the NPS category), or the 6.5% who have used cannabis (i.e., one specific 
drug rather than a category encompassing many drugs) in the last year. A more detailed analysis 
suggests that over half of the 0.7% of last-year NPS users reported a herbal smoking mixture (i.e., 
synthetic cannabis) as the substance taken on their last occasion of NPS use, a fraction of the 
number using actual cannabis. Finally, if we examine the limited figures for NPS prevalence on an 
individual basis the scale of the problem again seems to shrink: for example, 0.3% of the adult 
population reported last-year use of mephedrone, reportedly the most popular NPS in the UK, 
compared with the 1.5% who used ecstasy or the 2.2% using cocaine (Lader, 2016). For the vast 
majority of NPS, the number of users will be much smaller again.  These figures should, however, be 
read with the proviso that there will of course also be considerable unintended use of NPS by users 
who have attempted to, for example, purchase a substances such as LSD and have, often without 
even realising it, been instead sold a substance such as NBOMe (Martins et al, 2017). 
 
Various academics have questioned the dominant discourse around the size and seriousness of the 
NPS issue.  Reuter (2011:4) has described the problem as  ‘modest and localised ?, and points out that 
major disasters and violent markets have not been a problem particularly associated with NPS to 
date, although a few notable exceptions have emerged, including multiple fatalities in Russia 
associated with a particular strain of synthetic cannabis (RT News, 2014) and a localised outbreak of 
HIV associated with NPS injection in Dublin, Ireland (Giese et al, 2015).  Birdwell et al. (2011) further 
elaborate that it is unusual for an NPS to cause widespread and significant problems and van 
Amsterdam et al (2013:317) contend that 98% of NPS are little more than  ‘one-night wonders ?.  
Finally, EMCDDA (2013) figures suggest that, of the 73 NPS discovered in 2012, more than 50 were 
slightly different varieties of synthetic cannabinoid receptor agonists, further contextualising the 
range of substances discovered.  Taken collectively, these tendencies to (i) collect statistics on NPS 
as a group rather than as individual substances, (ii) retain NPS that have not remained in use, and 
(iii) record every small variation as a newly discovered substance, have led to an inflation of the size 
and scale of the NPS problem.  Alongside these quantitative points we should recognise the 
qualitative aspect of the often sensationalist nature of media coverage of NPS (a full discussion of 
which is beyond the scope of this paper, but see, e.g., Daly, 2016, Forsyth, 2012 and Sare, 2011 on 
media coverage and its influence on policy responses to mephedrone in the UK). All this has 
encouraged NPS to be viewed as one of the most pressing problems facing drug policy makers today, 
which has had important consequences in terms of the direction of funding, resources and expert 
attention to this relatively small part of the overall drugs issue.  As we shall see below, this has had 
further significant consequences in terms of policy development.    
 
The issues outlined above arise because NPS are often treated as one distinct category of drugs and 
thus provide an example of obscuring the differences within the NPS category.  Other public 
discourse related problems arise because the similarities between NPS and existing illicit substances 
are obscured.  For example, the emerging body of literature on NPS use amongst vulnerable 
populations such as the homeless, those who are imprisoned, and pre-existing dependent drug users 
(e.g. Blackman & Bradley, 2017; Ralphs et al, 2017; Quintana et al, 2017; Alexandrescu, 2017a) 
suggests that these groups are experiencing important problems because of NPS use.  In the UK, 
outbreaks of synthetic cannabis use in prisons or amongst homeless populations have resulted in 
protests from the media about the vile nature of these substances and the damage they are doing to 
our vulnerable populations.  Yet, as Alexandrescu (2017b:1) points out, drug epidemics of any kind 
are symptomatic of  ‘deeper, structural economic problems and inequalities ? rather than inherent to 
the individual substances themselves.  Vulnerable populations such as the homeless or those who 
are imprisoned are not experiencing problems for the first time because of the arrival on the scene 
of synthetic cannabinoids or other NPS; they are experiencing problems related to wider societal 
inequalities, part of which manifests as problematic use of whatever substances are available to 
them.  The pertinent point here is that, rather than being treated as a distinct issue affecting these 
populations, the use of NPS should be seen as an extension of existing problematic drug use: the 
similarities in causes and circumstance of use between existing illegal substances and NPS are 
greater in these cases than are the differences.   
 
Policy 
The consequences of the emergence of NPS as a distinct and cohesive category of drugs have been 
significant and profound in terms of national and international drug policy development, as partially 
explored already in our introduction.  The problem posed by NPS, in policy terms, is that existing 
systems of drug control tend to be sluggish in their reaction to emerging drug markets: a new 
substance is developed, marketed, gains in popularity, comes to the attention of the authorities and, 
where warranted, is eventually added to the list of controlled substances.   NPS, however, tend to 
emerge much more rapidly and often in tandem with each other, making it difficult for existing drug 
control systems to keep pace with developments.  Once legislation is passed to prohibit a substance, 
the offending compounds can be easily moderated to create a huge number of slightly different 
substances (van Amsterdam et al, 2013) in what has been characterised as a  ‘cat and mouse game ? 
(Measham et al, 2010).  Increasingly, demands have thus been placed on national and international 
drug control systems to adapt their existing drug laws to make them more effective in responding to 
NPS (Measham, 2013). 
 
The significance placed on the issue of NPS, combined with the perception of existing legislation as 
unfit to contain them, has led to the development of a raft of new measures that have been readily 
added to the table of policy options by an increasing number of countries, and which have 
fundamentally changed the landscapes of drug policy provision.  For example, traditionally, drug 
legislation lists individual substances which are to be controlled, but systems have been developed, 
in response to the rise in focus on NPS, which allow chemical compounds that are structurally similar 
(generic model) or which are perceived to have similar effects (analogue model) to existing 
controlled substances to be automatically controlled at any one time.  Elsewhere emergency 
legislation has been introduced that allows a substance to be immediately banned for a specific 
period without undertaking the lengthy evaluations of harm usually necessary to bring a substance 
under permanent control.  Finally, a handful of countries (listed previously) have established a 
blanket ban system whereby any substance meeting certain criteria (i.e. psychoactivity, however 
legally defined) are pre-emptively subjected to a total ban (Chatwin, 2014).  Even in countries such as 
New Zealand where the desire to create a regulated market for substances with low levels of harm 
exists, the obstacles to creating such a market have, thus far, remained insurmountable, resulting in 
a defaulting to banning on the basis of psychoactivity (Wilkins & Rychert, 2017).  
 
ĂĐŚŽĨƚŚĞƐĞŶĞǁŵĞĂƐƵƌĞƐĂƌĞďĂƐĞĚŽŶƚŚĞ ‘ƉƌĞĐĂƵƚŝŽŶĂƌǇƉƌŝŶĐŝƉůĞ ? (Hughes & Winstock, 2011), 
representing a significant change in drug policy.  Traditionally, the prohibition of substances and 
criminalisation of their users has been justified by establishing that they represent a significant 
harm, to both individuals and communities.  Systems such as analogue, generic, emergency and 
blanket-ban legislation dispense with this need to establish harm as a justification for prohibition, 
and instead presume that, because the substances are  ‘psychoactive ?, they are likely to be harmful. 
Prohibition is therefore justified as a precautionary measure.  Measham & Newcombe (2016) have 
thus revised the characterisation of the relationship between NPS development and policy change 
ĨƌŽŵ ‘ĐĂƚĂŶĚŵŽƵƐĞ ?ƚŽ ‘ŚĂƌĞĂŶĚŚŽƵŶĚƐ ? ?ǁŚĞƌĞďǇƚŚĞƐƉĞĞĚŽĨƉŽůŝĐǇĐŚĂŶŐĞŝƚƐĞůĨďĞĐŽŵĞƐŽŶĞ
of the important drivers of future NPS innovations. This means that a  ‘modest and localised ? (Reuter, 
2011:4) facet of the overall drug problem has led to fundamental changes in the way that we control 
drugs at both the national and the international level (the EU is currently proposing changes to 
European drug control (Chatwin, 2017)).   
 
Collectively, these policies represent a move away from harm reduction and evidence based policy 
and a return to stricter policies in a move that Stevens & Measham (2014) have described as part of 
ƚŚĞ ‘ĚƌƵŐƉŽůŝĐǇƌĂƚĐŚĞƚ ? PƌĞƐƉŽŶĚŝŶŐƋƵŝĐŬůǇďĞĐŽŵes all important and, in the absence of scientific 
evidence, the tendency for policy makers is to err ever more heavily on the side of caution.  
Ironically, this means that the focus on NPS as a new, distinct and important facet of the drugs 
problem, once seen by some as an opportunity for the development of innovative strategies of drug 
control (for example, Seddon 2014), has actually resulted in a return to older and more stringent 
methods of drug control that echo war on drugs mentalities.  It is therefore evident that the 
tendencies to view NPS as one distinct category of substances, and to view this category as 
inherently separate from existing substances, has had far-reaching and wide-ranging consequences 
in terms of the development of drug policy in general. 
 
Theory 
These obfuscations also undermine our ability to develop theoretical understandings of the 
contemporary drug landscape. Again, part of this problem is the artificial separation of NPS from 
drugs more generally, rather than the conceptualisation of NPS as merely the next chapter in our 
history of narcotica (Boothroyd, 2016). History demonstrates that some members of society will 
seek out whatever mind-altering substances are available to them, whether to cope with negative 
circumstances or to embrace positive benefits (e.g., Karlsson, 2010). Aside from the NPS 
phenomena, we see other contemporary changes in patterns of drug use  W such as the resurgence of 
opiate use (van Amsterdam & van den Brink, 2015) or the abuse of prescription medicines (Wilson, 
2016).  Similarly, in terms of drug supply we have seen other recent changes, including the 
development of online drug markets (Barratt and Aldridge, 2016 ) ?ƚŚĞƐƉƌĞĂĚ ? ‘ŐůŽĐĂůŝƐĂƚŝŽŶ ? )ŽĨ
cannabis cultivation (Decorte & Potter, 2015; Decorte et al., 2011) and the domestic production of 
other drugs (UNODC, 2016). The growth (predominantly online) of forums for discussing drug use  W 
for peer-peer advice, user-experience/trip-reports, harm reduction strategies, etc  W is also 
noteworthy (Boothroyd & Lewis, 2016).  The point is that patterns and trends in drug use, drug 
markets and drug harm reduction change, as they always have, in relation to wider social, cultural 
and economic conditions. 
 
The tendency to focus on NPS themselves as the latest trend in drug policy means that important 
opportunities to develop wider and more enduring understandings of drug use, that encompass but 
are not limited to the rise in range and availability of NPS, are lost.  To date, despite the scramble for 
the development of profound policy changes in the area of NPS, there has been little attempt to link 
NPS use to existing theoretical standpoints (but see, e.g., Griffiths et al., 2010, Barratt and Lenton, 
2013, and Potter, 2014, for some discussion along these lines).   For example, if we were to focus on 
socio-technological developments as the most significant recent development in patterns of drug 
use, a very different theoretical picture would emerge.  Changes in technology have certainly played 
a significant role in the changing nature of drug use in recent years: chemical and horticultural 
techniques enable the development of new drugs and the production of old ones; new media 
technologies facilitate the connections between interested actors, the dissemination of information, 
and even the distribution of drugs. In this way, the rise in NPS use should be viewed as part of a 
landscape of wider drug-scene developments with connections to more general trends of later 
modernity and globalisation, rather than as a distinct phenomenon.   
 
Elaborating on this, there are many different versions of late (post, high) modernity theory, but the 
starting point for most is not (just) that the contemporary social world is fundamentally different 
ĨƌŽŵƚŚĞ ‘ŵŽĚĞƌŶ ?ĞƌĂ ?ďƵƚƚŚĂƚĐŚĂŶŐĞŝƐ perpetual and accelerating. This constant change is 
facilitated by technological advances and socio-economic developments, with those two strands 
inter-dependent. In terms of understanding the social world, a key difference from earlier modernity 
is that humans (as individuals, communities, nation states or as a global society) struggle to respond 
to this rapid and unceasing change. Hence, Bauman (2000; 2007) talks of  ‘liquid modernity ?, and how 
the increasingly fluid nature of contemporary life poses seriŽƵƐĐŚĂůůĞŶŐĞƐƚŽƚŚĞ ‘ƐŽůŝĚ ?ŝŶƐƚŝƚƵƚŝŽŶƐ
(economic, political, cultural) of an earlier modernity; Young (2007) uses the metaphor of vertigo  W 
the individual and collective dizziness experienced as we have fewer rigid points to anchor ourselves 
to in an ever-changing, uncertain world.  
 
NPS ŚĂǀĞďĞĞŶĂŶĂůǇƐĞĚƚŚƌŽƵŐŚƚŚĞůĞŶƐŽĨ ‘ůŝƋƵŝĚŝƚǇ ?by DČbrowska and Bujalski (2014), referring 
not just to the (ever changing) substances and their effects, but also to the fluid nature of the way 
they have been marketed (legally and illegally, online and off), the cultural scenes in which they have 
been used, and the portrayal of all these aspects in the media.  A focus exclusively on NPS, however, 
obscures the fact that the development of online drug markets and user forums, and of domestic 
production of cannabis, methamphetamine and other drugs, fit the same pattern. All are driven by 
tĞĐŚŶŽůŽŐŝĐĂůĚĞǀĞůŽƉŵĞŶƚƐ ?ĂůůĨŝƚĞĐŬ ?Ɛ ? ? ? ? ? )ŝĚĞĂŽĨ ‘ŵĂŶƵĨĂĐƚƵƌĞĚƌŝƐŬ ? W initially beneficial 
scientific advances leading to unforeseen new challenges and risks. At the same time, media and 
policy responses fit the characteristics of vertigo, and of a reflexive society struggling to keep up. 
None of this is new, as such, and the general trends (if not the specific forms) of NPS, online supply, 
virtual cultural networks and domestic drug production  W and social responses to these  W should 
really have been predictable. 
 
Toffler (1970), for example, described nearly 50 years ago how the exponential rate of technological 
ĂĚǀĂŶĐĞŵĞŶƚĂŶĚĂĐĐŽŵƉĂŶǇŝŶŐƐŽĐŝĂůĐŚĂŶŐĞůĞĂĚƐƚŽ ‘ĨƵƚƵƌĞ ƐŚŽĐŬ ? Wbreakdown in an increasing 
number of institutions (and individuals) that evolved under the less complicated conditions of early 
modernity and prove unable to cope with the challenges of constant change. NPS policy, and the 
desperate  W but flawed  W efforts of blanket ban legislation fit this model, but should not been seen 
as an isolated case.  Responding effectively to developments in domestic production, online markets 
and drug-related social media encounters similar difficulties. Further, academic tendencies to try to 
ĐŽŶĐĞƉƚƵĂůŝƐĞƚŚĞ ‘ŶĞǁ ?ĂƐƐŽŵĞƚŚŝŶŐƐĞƉĂƌĂƚĞ ?ǁŚĞƚŚĞƌ because they are following the lead from 
policy-makers or not) are part of the same problem and unlikely to offer solutions (whether in the 
form of effective policies or of serious and relevant sociological theories). Of course, academics 
ŽĨƚĞŶŚĂǀĞƚŽ ‘ĨŽůůŽǁƚŚĞŵŽŶĞǇ ? ?ƌĞƐĞĂƌĐŚŝŶŐĂƌĞĂƐǁŚĞƌĞĨƵŶĚŝŶŐŝƐĂǀĂŝůĂďůĞǁŚŝĐŚŝƚƐĞůĨƌĞĨůĞĐƚƐ
what politicians, policy makers and funding bodies (in turn, influenced by the media) perceive as the 
 ‘ŚŽƚƚŽƉŝĐƐ ?ŽĨƚŚĞĚĂǇ ?dŚĞĐĂƐƵĂůŝǌĂƚŝŽŶŽĨĂĐĂĚĞŵŝĐƉŽƐƚƐ ?ĂŶĚƚŚĞ need for non-tenured 
researchers to win funding to maintain their own employment, are themselves features of the late-
modern employment landscape (ĂůƐŽĂŶĂƐƉĞĐƚŽĨĞĐŬ ?Ɛ ? ? ? ? ? ) ‘ƌŝƐŬƐŽĐŝĞƚǇ ?), further illustrating 
how we need to consider broader social (as well as scientific) changes to fully understand the 
contemporary drug situation! 
 
Of course, the discussion above provides just one example of the benefits of viewing developments 
in use and prominence of NPS as part of our wider social and cultural understandings of drug-scenes 
in general.  Alternative, and equally useful, analyses could be drawn from seeking to understand NPS 
ƚŚƌŽƵŐŚƚŚĞůĞŶƐŽĨ ?ĨŽƌĞǆĂŵƉůĞ ?ŵŽƌĂůƉĂŶŝĐƚŚĞŽƌǇŽƌŚƌŝƐƚŝĞ ?ƐĐŽŶĐĞƉƚƵĂůŝƐĂƚŝŽŶŽĨĚƌƵŐƵƐĞƌƐĂƐ
ƚŚĞ ‘ŐŽŽĚĞŶĞŵǇ ? (Christie & Bruun, 1985).  The point to emphasise here is that the creation of NPS 
as a distinct category and as a phenomenon separate from established drugs scenes discourages 
these kind of analyses.  There have been some attempts to apply existing theories to the NPS 
phenomenon  W see, for example, the aforementioned work on NPS and liquid modernity (DČbrowska 
and Bujalski, 2014) or Alexandrescu (2015) on moral panic theory and injecting NPS users ? ?,ŽƌƐĞůǇ ?Ɛ
(2017) critique of moral panic theory as overused, reductionist and outdated notwithstanding, the 
NPS example of media portrayal  W and exaggeration  W of both the extent and related harms of a 
social phenomenon particularly associated with demonised sub-cultural groups, the inputs from 
ƵŶ ?ĚĞƌ )ŝŶĨŽƌŵĞĚ ‘ĞǆƉĞƌƚƐ ? ?ĂŶĚƚŚĞƌĞƐƵůƚŝŶŐĞǆĐĞƐƐŝǀĞƉŽůŝĐǇƌĞƐƉŽŶƐĞƐĚŽĞƐƐĞĞŵƚŽfit the criteria 
of moral panic. However, a full discussion is beyond the scope of this paper.)  But we are advocating 
here for more than this: for the conceptualisation of NPS, not as a new and distinct issue from the 
rest of the drug scene, but as an important part of it that is inextricably tied up with wider drug-
scene changes (in markets, production, information sharing practices, etc.) and wider societal 
changes (the liquidity of late modernity, the exponential increase in the advance of technological 
ability, etc.).  The rise in prominence of NPS cannot be effectively understood without viewing it as a 
part of the bigger social, cultural and theoretical picture with which we are already familiar.  
 
Conclusions  
tĞĂƌĞŶŽƚĐĂůůŝŶŐĨŽƌĂŶĞŶĚƚŽƌĞƐĞĂƌĐŚŝŶ ‘ŶĞǁ ?ĚƌƵŐƐ ?ďƵƚǁĞĂƌĞĂƐŬŝŶŐĨŽƌĐƌŝƚŝĐĂůƌĞĨůĞĐƚŝŽŶŽŶ
the use of NPS as a category. Sometimes, the focus should be on specific substances  W particularly 
when looking at health issues that relate to biochemical interactions. In other circumstances, we 
should look at drugs in general  W particularly when it is the socio-economic conditions driving drug 
use that interest us. Comparisons between legal and illegal drugs, and the cat-and-mouse (or hare-
and-hounds) situation of new drugs being developed specifically as legal alternatives to prohibited 
substances, are of interest when considering the deterrent effect or harmful consequences of 
particular policies. But rarely does academic work nor public discourse focusing on NPS as a category 
fit these examples, ĞƐƉĞĐŝĂůůǇǁŚĞŶƚŚŽƐĞEW^ƚŚĂƚŵŝŐŚƚŽŶĐĞŚĂǀĞďĞĞŶ ‘ůĞŐĂůŚŝŐŚƐ ?ĐĞĂƐĞƚŽďĞ
legal. 
 
The uncritical categorisation of NPS, as a group of drugs separate from established substances, is 
unhelpful. It has facilitated over-estimations of the size and scale of the problem and a tendency to 
ignore the underlying conditions that stimulate patterns of drug use.  It has contributed to significant 
and profound policy changes that have included a tendency to ignore the need to reduce the harm 
done by substances themselves and the policies employed to control them, in favour of a return to 
more repressive styles of drug control.  Finally, it has proved a distraction from wider efforts to 
understand the societal and cultural contexts within which drug use occurs.   
 
We contend that the real challenges for drug policy today, rather than pursuing ever more draconian 
control options, are, as they have long been, to determine how to reduce harm, how to reach out to 
vulnerable populations and how to reduce inequalities in society in general.  In terms of theoretical 
conceptualisations of drug use, the need is not to apply existing theories to NPS as an isolated case, 
but to view NPS as just one part of the ever changing face of contemporary drug use and to seek to 
interrogate wider social and cultural theories for their usefulness in explaining not just the rise in 
prominence of NPS, but also other recent developments including, but not limited to, around online 
drug markets or the blurring of boundaries between the licit and illicit.  NPS are Not Particularly 
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